Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$142.07 USD

142.07
79,521

+2.13 (1.52%)

Updated Oct 9, 2024 12:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Edwards Begins US CENTERA Study, Reintroduces Valve in Europe

by Zacks Equity Research

Edwards (EW) is recommencing commercial introduction of CENTERA valve in Europe after making certain minor modification to CENTERA's delivery system.

Here's Why You Should Hold Ecolab Stock in Your Portfolio

by Zacks Equity Research

Despite fluctuations in the cost of raw materials, Ecolab (ECL) to gain from strong performance in the Global Industrial segment.

    The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom

    Here's Why You Should Invest in Genomic Health (GHDX) Now

    by Zacks Equity Research

    Genomic Health (GHDX) continues to see increasing private coverage for the Oncotype DX GPS test.

    GNC Holdings E-Commerce Business Solid, Competition Rife

    by Zacks Equity Research

    GNC Holdings (GNC) continues to register strong performance in e-commerce business. A competitive landscape is a threat.

    Express Scripts' Accredo & Akcea Tie Up to Distribute TEGSEDI

    by Zacks Equity Research

    Express Scripts (ESRX) likely to gain market traction through distribution of TEGSEDI.

    CVS Health's Aetna Deal Imminent, PBM Selling Season Strong

    by Zacks Equity Research

    CVS Health (CVS) is steadily approaching the Aetna deal wrap-up. Per the company, this significant buyout might alter the whole Healthcare landscape in the United States.

    Teleflex's Latest Essential Medical Buyout to Broaden Suite

    by Zacks Equity Research

    Teleflex (TFX) acquires Essential Medical to strengthen hold in the high-potential structural heart and endovascular aneurysm repair markets.

    Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now

    by Zacks Equity Research

    Strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select international markets bode well for Tandem Diabetes (TNDM).

    Nabaparna Bhattacharya headshot

    Wearable Medical Device Boom Puts These 3 Stocks in Focus

    by Nabaparna Bhattacharya

    Americans depend on wearable medical devices for fitness tracking, blood pressure maintenance, self-glucose monitoring and more. Here, we discuss major companies that are raking in huge profits.

    Here's Why You Should Invest in Henry Schein (HSIC) Stock

    by Zacks Equity Research

    Henry Schein's (HSIC) strategy to extend digital dentistry globally is encouraging. Recent acquisitions will strengthen its foothold in the high-potential dental market.

      Varian (VAR) & Reliance Group Tie Up to Enhance Cancer Care

      by Zacks Equity Research

      Varian (VAR) enjoys solid presence in Asia, Latin America and Africa's cancer care space.

        Here's Why You Should Hold Medidata Stock in Your Portfolio

        by Zacks Equity Research

        Medidata's (MDSO) Clinical Cloud platform is likely to provide it a competitive edge in the MedTech space. However, cutthroat competition in the niche space is a headwind.

          Will Walgreens (WBA) Q4 Earnings Gain From Overall Strength?

          by Zacks Equity Research

          Several planned developments, early benefits of new pharmacy contracts as well as an increase in volume are consistently driving growth within Walgreens Boots' (WBA) Retail Pharmacy USA division.

            Europe Okays Use of Insulet's (PODD) Omnipod With Fiasp

            by Zacks Equity Research

            Fiasp's operative efficiency coupled with Insulet's (PODD) Omnipod System will provide a new option for both patients and prescribers to support their diabetes management requirements.

              Genomic Health's New Data on Oncotype DX GPS to Boost Uptake

              by Zacks Equity Research

              Genomic Health (GHDX) continues to see positive developments within the U.S. prostate cancer test business.

                Thermo Fisher (TMO) Scales a 52-Week High: What's Driving It?

                by Zacks Equity Research

                Thermo Fisher (TMO) sees strength in all end markets, categorized either by customer type or geography.

                  Here's Why You Should Hold Integer Holdings in Your Portfolio

                  by Zacks Equity Research

                  Integer Holdings' (ITGR) new strategy to drive sales and profit growth to provide the company with a competitive edge in the MedTech space.

                    Merit Medical (MMSI) to Acquire Cianna Medical, Shares Up

                    by Zacks Equity Research

                    Merit Medical (MMSI) to leverage on Cianna Medical's SAVI and SCOUT platforms. The company plans to retain Cianna Medical's commercial and R&D teams after closure of the transaction.

                      Boston Scientific Grows on Acquisitions, Product Launches

                      by Zacks Equity Research

                      Boston Scientific's (BSX) strategy to extend its existing portfolio through inorganic growth profile has been advancing well. Further, this should help aid the company's top line in the long term.

                        Abbott's CE Mark for FreeStyle Libre 2 Boosts Diabetes Arm

                        by Zacks Equity Research

                        Abbott (ABT) focuses on boosting diabetes care. The latest CE Mark will increase the top-line contributions from the Diabetes unit.

                          Here's Why You Should Invest in CVS Health (CVS) Stock Now

                          by Zacks Equity Research

                          CVS Health's (CVS) solid cash position is encouraging. Strong 2019 PBM selling season is another upside.

                            Here's Why You Should Buy Inogen (INGN) Stock Right Now

                            by Zacks Equity Research

                            Inogen (INGN) is expected to gain from strong international foothold and a raised view for 2018.

                              Baxter Collaborates With Mayo Clinic to Open Renal Care Center

                              by Zacks Equity Research

                              Per the agreement, Baxter (BAX) and Mayo Clinic researchers to form an outpatient clinic for kidney disease management, home dialysis and in-center dialysis services.

                                Henry Schein's 3 Investments to Fortify Dental Implant Arm

                                by Zacks Equity Research

                                Intra-Lock, Medentis Medical and Pro-Cam Implants jointly are likely to prove conducive to growth for Henry Schein's (HSIC) existing implant-based tooth replacement solutions line.